Quick Links
Main Menu
More Links

Latest Nursing Jobs &
Clinical Update Alerts!

Subscribe to get timely notifications.

Latest Nursing Jobs Vacancies
NCLEX & CGFNS Practice Questions

EMA recommends combination therapies for chronic hepatitis C virus

EMA recommends combination therapies for chronic hepatitis C virus

Sofosbuvir/velpatasvir and grazoprevir/elbasvir found to offer choice and better targeting of genotypes.

Two new combination therapies that have the potential to cure patients with long-term hepatitis C virus (HCV) infection and rule out the need for interferon are being recommended for approval across the EU.

The European Medicines Agency (EMA), which evaluates medicinal products for use in EU, is proposing that marketing authorisation is given to sofosbuvir/velpatasvir (Epclusa; Gilead Sciences) and grazoprevir/elbasvir (Zepatier; Merck Sharp & Dohme).

Both products are direct-acting antivirals, which block the action of proteins that are essential for viral replication. Treatment with them also means that patients do not need to take interferons, which are traditionally poorly tolerated and have serious side effects.



The sofosbuvir/velpatasvir combination targets the proteins NS5B and NS5A, as well as all six genotypes of HCV, while grazoprevir/elbasvir targets the proteins NS3/4A and NS5A and genotypes 1 and 4.

The recommendations follow the results of clinical trials involving patients whose hepatitis C status was tested 12 weeks after taking the combination therapies.

For patients taking sofosbuvir/velpatasvir, researchers found that HCV was no longer detected in the blood 12 weeks after the end of treatment, with or without ribavirin. More than 90% of patients across all genotypes had no detectable HCV in their blood at the end of the trial, and could be considered as ‘cured’ of the virus. The sustained virologic response rate for patients with genotype 3 was around 90%.

More than 90% of patients given grazoprevir/elbasvir had no detectable hepatitis C virus in their blood at 12 weeks. The therapy was particularly effective in patients with chronic kidney disease who usually have a poor prognosis.

The recommendations by the EMA’s Committee for Medicinal Products for Human Use (CHMP) will now go the European Commission for marketing authorisation to be approved.

Sofosbuvir is already available in the EU under the brand name Sovaldi, and as a combination therapy with ledipasvir (Harvoni).

“The major step forward is [sofosbuvir/velpatasvir], which means that there is now a good treatment for genotype 3 hepatitis C,” says Steve Ryder, a consultant physician in hepatology and gastroenterology at the Faculty of Medicine and Health Sciences at the University of Nottingham.

“Almost half of UK patients have this strain and it didn’t respond well to the previous generation of oral treatments… so this is very good news for a group of patients who currently still have to take interferon-based treatments.”

He says grazoprevir/elbasvir is a good combination for genotypes 1 and 4, but adds that there are already “very effective treatments for these genotypes so its main benefit is to potentially provide more choice and drive down the very high cost of these medicines”.

Ryder says the cost of the drugs will affect whether or not they will become available on the NHS.

“NHS England has placed great restrictions on access to Harvoni,” he says. “Many other nations have done much more intelligent deals with pharma that both protect the drug budget but give much better access to treatment than we have [in the UK] – Australia and Israel are good examples.”



The CHMP’s recommendations were welcomed by the charity Hepatitis C Trust. Its chief executive, Charles Gore, says: “More drugs mean more competition, which generally means lower prices. At the same time these drugs work for all genotypes so we should be able to consign the use of interferon to history, even for genotypes 2,3, 5 and 6, which will be a huge benefit and an enormous relief to people living with hepatitis C.”

In May 2016, the World Health Organization published the first ever global viral hepatitis strategy, which sets a worldwide target to eliminate viral hepatitis B and C by 2030. The strategy was unanimously supported by the 194 member states of the World Health Assembly at a meeting on 23–26 May 2016.

Citation: The Pharmaceutical Journal, PJ May 2016 online, online | DOI: 10.1211/PJ.2016.20201234

CLICK HERE for more resources on Gastrointestinal Care

Heart risks with newer hepatitis C drugs and amiodarone

The European Medicines Agency (EMA) has warned against the use of antiarrhythmic amiodarone in combination with newer hepatitis C infection treatments, after reports of heart problems in eight patients.

In a review of patients taking amiodarone who then started taking Harvoni (sofosbuvir with ledipasvir) or a combination of Sovaldi (sofosbuvir) and Daklinza (daclatasvir) to treat a hepatitis C infection, there were eight reports of severe bradycardia (slow heart rate) or heart block (problems with conduction of electrical signals in the heart) within the first 12 days of starting the antivirals. Most problems occurred as early as the first day of treatment. Two of these patients needed pacemakers and one patient died from a cardiac arrest.

While it’s not yet clear why this has happened, the EMA has recommended that patients taking these hepatitis C medications should avoid taking amiodarone. If no other antiarrhythmics are suitable, the patients should be monitored closely, potentially in hospital for the first 48 hours. They should also be told to report any symptoms to their doctor straight away, including slow heartbeat, dizziness, faintness, unusual tiredness, shortness of breath or chest pain. Since amiodarone has a long half-life, patients should also be monitored if they have stopped taking the drug in the past few months.

Source: The Pharmaceutical Journal, PJ August 2015 online, online | URI: 20069234

Prevention of Liver Cancer Through the Early Detection of Risk-Related Behavior Among Hepatitis B or C Carriers

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the leading causes of liver cirrhosis and hepatocellular carcinoma. Little is known about the relationship between health-related behaviors and health status among HBV or HCV carriers.

Objective: The purpose of this study was to explore the relationship between health status (eg, specific biomarkers) and health-related behaviors (eg, alcohol consumption) in individuals with or without HBV or HCV infection.

Methods: A cross-sectional descriptive design was used, and a community-based health screening survey was conducted between August 2011 and July 2012 in Taiwan.

Click HERE to read more about this.

WhatsApp No.: +2348055338879
Website Design Company in Lagos, Nigeria - CKDigital